Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ACT-1014-6470 in Healthy Subjects
NCT04183686Phase 1Completed
- Sponsor
- Idorsia
- Start
- Nov 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ACT-1014-6470 in autoimmune diseases (10 arms), sponsored by Idorsia. Primary endpoint: Area under the plasma concentration-time curve from zero to infinity up to 3 weeks. Started Nov 2019; status: completed.
02
Drugs
ACT-1014-6470
03
Conditions
autoimmune diseases
Beyond the preview
Go deeper on NCT04183686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04183686.